Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is an 8-aminoquinoline used in the treatment of malaria. Oral administration. Single daily dose for 14 days.
It is excreted in human milk in a clinically non-significant amount, no problems have been observed in infants whose mothers took it and the plasma levels of these infants were either very low or below the limit of detection. (Gilder 2018)
WHO List of Essential Medicines 2002: compatible with breastfeeding in healthy newborns, avoid, if possible, in premature infants and children under one month due to the risk of jaundice. (WHO 2010 and 2002)
Avoid in glucose-6-phosphate-dehydrogenase deficiency (G6PD) (CDC 2019, Lalloo 2016, Chen 2010, WHO 2010 and 2002), although the extremely low dose of primaquine received through the mothers’ milk has been found to be highly unlikely cause hemolysis in G6PD-deficient infants. (Brummaier 2020, Watson 2018, Saito 2018, Gilder 2018)